August 2012
-
DDL 21 kicked off on Wednesday, December 8 with an EPAG workshop on the abbreviated impactor measurement (AIM) technique attended by 85 inhalation scientists who elected to attend the workshop in addition to the main… Read more . . .
-
Over the past few years, it has become increasingly difficult to ignore the rising cultural influence of social media. One of this year’s top movies documents the founding of Facebook; even major news outlets report… Read more . . .
-
David Cipolla, Aradigm A number of outstanding books have been written for medical practitioners who treat lung disease, including Murray and Nadel’s Textbook of Respiratory Medicine and Farzan’s Concise Handbook of Respiratory Diseases. These books… Read more . . .
-
Australian company Pharmaxis is launching its Aridol inhaled dry powder mannitol bronchial challenge test in the US. The FDA approved the product in October 2010 for the assessment of bronchial hyperresponsiveness in patients 6 years… Read more . . .
-
The Asthma and Allergy Foundation of America (AAFA) has published its annual list of US “asthma capitals,” led this year by Richmond, Virginia. The list ranks 100 metropolitan areas in terms of difficulties that they… Read more . . .
-
Submit abstracts online at www.omicsonline.org/BABE2011/abstract.php or email to BABE2011@omicsonline.org. See abstract submission tracks. Read more . . .
-
A dosage trial of Verona Pharma’s inhaled mixed phosphodiesterase (PDE) 3/4 inhibitor RPL554 for the treatment of mild asthma has demonstrated positive bronchodilation without any significant adverse effects at dosages two and four times higher… Read more . . .
-
Since October 1, 2010, Vectura’s financial performance has exceeded the board’s expectations, according to the company’s interim management statement. Chief Executive Chris Blackwell attributes the improved performance to a restructured R&D program and says that… Read more . . .
-
Scott R. Ward has been named Chairman of the Board of Directors by MAP Pharmaceuticals, replacing Staven A. Elms. MAP plans to submit an NDA for its Levadex inhaled ergotamine for the treatment of migraine… Read more . . .
-
North Carolina specialty pharma company Inspire Pharmaceuticals has announced that it is cutting 27% of its workforce (65 jobs) after its denufosol inhalation solution for the treatment of cystic fibrosis failed a Phase 3 trial.… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland